Drugs / MyoCell™
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00050765 | Aug 2006 | congestive heart failure, coronary artery disorder, myocardial infarction | Bioheart, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT00054678 | Feb 2003 → Oct 2007 | congestive heart failure, coronary artery disorder, myocardial infarction | Bioheart, Inc. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT00526253 Comparator | Sep 2007 → Feb 2019 | congestive heart failure | Bioheart, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MyoCell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00054678 ↗ |
| Modality | Cell therapy | “MyoCell™ consists of patient autologous skeletal myoblasts which are expanded ex vivo” NCT00050765 ↗ |
| Route | Other | “via epicardial injection” NCT00050765 ↗ |